Covovax

	DCGI approves market authorisation for SII's Covid vaccine Covovax as heterologous booster dose Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. published on : 17th January 2023
	Commercial use of SII’s Covovax as heterologous booster jab gets government nod According to officials, the subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO), which met on Wednesday, deliberated on the issue. published on : 13th January 2023
	COVID-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar Poonawalla Covovax works very well against omicron variant,more than Covishield, says Adar Poonawalla. published on : 9th January 2023
	SII seeks nod to export 32.4 lakh doses of its Covid vaccine Covovax to US The sources said it will be the first instance of any Indian manufacturer's vaccine -- Covid or non-Covid -- to be exported to the US. published on : 30th June 2022
	Government panel recommends emergency approval for SII's Covovax for 7-11 year olds The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9. published on : 24th June 2022
	SII's COVID vaccine Covovax now available for 12-17 age group at private centres Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal. published on : 2nd May 2022
	Poonawalla warns against return to business-as-usual approach Calling for increased adoption of booster doses, Poonawalla said it is also needed because people need to travel internally and outside, many countries have made booster doses mandatory for travel. published on : 22nd April 2022
	Panel seeks more data on Serum Institute's EUA application for Covovax use The SII had last month submitted an application to the Drugs Controller General of India (DCGI) seeking emergency use authorisation (EUA) for Covovax's use among children in the age group. published on : 12th April 2022
	Govt panel recommends inclusion of Covovax in national Covid vaccination drive for those aged 12 and above India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group, subject to certain conditions, on March 9. published on : 3rd April 2022
	India's drugs regulator gives nod to phase-3 clinical trial of Covid vaccine Covovax CDSCO had recommended permission for conducting phase-3 clinical trial for Covovax as booster dose in adults who have been fully vaccinated with either Covaxin or Covishield least three months ago. published on : 23rd March 2022
	DCGI's EUA nod to SII's Covovax for 12-17 years age group Poonawalla says younger age groups to follow shortly published on : 9th March 2022
	Covid: Government panel recommends permission for phase-3 trial of Covovax as booster dose in adults The Drugs Controller General Of India (DCGI) has already approved Covovax for restricted use in emergency situations in adults on December 28. published on : 6th March 2022
	Covovax EUA recommended for 12-17 group The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 last year. It is yet to be used in India’s vaccination drive. published on : 5th March 2022
	Government panel recommends EUA for Covid vaccine Covovax for 12-17 age group The Drugs Controller General of India (DCGI) had approved Covovax for restricted use in emergency situation in adults on December 28. published on : 4th March 2022